Merck Serono picks second anticancer from Chinese partner
This article was originally published in Scrip
Executive Summary
Merck Serono has licensed a preclinical PARP inhibitor from the Chinese firm BeiGene. The deal comes after the German firm signed an agreement for a BRAF inhibitor from BeiGene in May (scripintelligence.com, 5 June 2013).